Full text
| |
| Author(s): |
André Luís Berteli Ambrósio
Total Authors: 1
|
| Document type: | Doctoral Thesis |
| Press: | São Carlos. |
| Institution: | Universidade de São Paulo (USP). Instituto de Física de São Carlos (IFSC/BT) |
| Defense date: | 2006-05-11 |
| Examining board members: |
Richard Charles Garratt;
Paula Regina Kuser Falcao;
Mario Sanches Matilde Junior;
Francisco de Assis Rocha Neves;
Glaucius Oliva
|
| Advisor: | Richard Charles Garratt |
| Abstract | |
Ajulemic acid (AJA) is a synthetic analog of the tetrahydrocannabinol (THC) metabolite THC-11-oic acid. THC is a major active ingredient of the drug marijuana derived from the plant cannabis sativa. It has been shown that AJA has potent analgesic and anti-inflammatory activity without the psychotropic action of THC. At therapeutic doses AJA is not ulcerogenic, making it a promising anti-inflarnatory drug. Furthermore, AJA is currently under phase I of clinical tests by Indevus Phmaceuticals (USA). However, the mechanism of AJA action remains unknown. It has been shown by biochemical assays that AJA binds directly and specifically to the peroxisome proliferators-activated receptor (PPAR) indicating that this may be a potential target for drug-development in the treatment of pain and inflammation. In this work we describe the crystal structure of the ligand binding region of this receptor in complex with ajulêmico acid, showing that in fact they may be partners in vivo, also providing structure-based answers for current questions, for example, the specificity for the isoform . The binding mode of AJA gives clues about modifications on its structure that might lead to development of more specific and potent molecules. In the second half, it is presented the crystal structure of macromolecular complex between the catalytic core domain of HIV-1 Integrase and the integrase-binding domain of LEDGF (also known as p75). Inspection of the crystallographic model suggests the presence of a specific interface, sharing a high number of tight contacts, apparent lentiviral tropism of LEDGF. Also, our results, along with in vitro assays previously reported, encourage efforts to exploit vim-host protein interactions for the development of novel antiretroviral drugs (AU) | |